ClinicalTrials.gg
TerminatedNCT07222189Updated Oct 22, 2026

A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)

A Phase 2 interventional study of balinatunfib and balinatunfib-matching placebo in Colitis Ulcerative and Crohn's Disease, sponsored by Sanofi. Terminated at 10 sites in 7 countries. Open to participants aged 19 Years to 77 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Why this study was terminated
Business decision
Updated Oct 22, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Non-randomized
Ages
19 Years to 77 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Colitis, Ulcerative by Sanofi — 3 open to participants now, 6 under way, 2 of them phase 3. Colitis, Ulcerative · Sanofi.

Enrollment
11th of 12
7 · median 87
Started
2026
with 2 others
Phase 2
8 of 12
none open now
Registered
11th of 12
by date

Among the 12 studies in Colitis, Ulcerative by Sanofi, this one is the 11th largest by enrollment, is one of 3 that started in 2026, is one of 8 in phase 2, and was the 11th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 12 studies in Colitis, Ulcerative by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 19 Years to 77 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Colitis, Ulcerative by Sanofi, or all of them as a file.
02

Study summary

LTS19689 is a multinational, multicenter extension study to evaluate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn's disease (CD) or ulcerative colitis (UC) who completed the 52-week treatment period (on balinatunfib or placebo) in the parent studies, SPECIFI-CD (DRI18212) or SPECIFI-UC (DRI17822), respectively.

  • The primary objective of this study is to assess the long-term safety and tolerability of different doses of balinatunfib in participants with CD or UC, as measured by the number and percentage of participants with CD or UC with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs) during the study period.
  • The study will consist of 2 independent cohorts through the study given the distinct nature of each disease:

    • CD Cohort: comprised of CD participants enrolled from SPECIFI-CD (DRI18212).
    • UC Cohort: comprised of UC participants enrolled from SPECIFI-UC (DRI17822).
  • The study will consist of the following study periods for each cohort:

    • A Double-Blind (DB) treatment period of up to 104 weeks for eligible participants from the DB maintenance phases of the respective parent studies.
    • An Open-Label (OL) treatment period of up to 104 weeks for:

      • Eligible participants from either the DB or OL periods of the parent studies,
      • Eligible participants who meet escape criteria at any time during the DB period of the LTS19689.
    • A 2-week follow-up period following the End of Treatment (EOT). The study duration will be up to 107 weeks, with the treatment duration up to 104 weeks.
03

Conditions studied

  • Colitis Ulcerative
  • Crohn's Disease
04

Who can participate

Ages eligible
19 Years to 77 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Participants with Crohn's Disease (CD) or ulcerative colitis (UC) who completed treatment at Week 52 of the SPECIFI-CD (DRI18212) or SPECIFI-UC (DRI17822) studies, respectively:

    • Participants with CD

      1. who complete double-blinded treatment at Week 52 of SPECIFI-CD (DRI18212) study;
      2. who complete open label treatment and achieve the appropriate outcomes at Week 52 of SPECIFI-CD (DRI18212) study.

        OR

    • Participants with UC

      1. who complete double-blinded treatment at Week 52 of SPECIFI-UC (DRI17822) study;
      2. who complete open label treatment and achieve the appropriate outcomes at Week 52 of the SPECIFI-UC (DRI17822) study.
  • use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Women participants should not be pregnant or breastfeeding

Exclusion criteria

Exclusion Criteria:

  • Participants with CD who develop a new medical condition precluding participation as described in Exclusion criteria of SPECIFI-CD (DRI18212) clinical trial protocol.
  • Participants with UC who develop a new medical condition precluding participation as described in Exclusion criteria of SPECIFI-UC (DRI17822) clinical trial protocol.
  • Participants who developed a new medical condition or a change in status of an established medical condition which (per Investigator's medical judgment) would adversely affect the participation in this study or would require permanent IMP discontinuation.
  • Participants who permanently discontinued IMP during the parent study or temporarily discontinued IMP for more than 14 consecutive calendar days by the time of Day 1 of LTS19689.
  • Participants who, during their participation in the parent study, developed an adverse event (AE) or a serious adverse event (SAE) deemed related to balinatunfib, which in the opinion of the Investigator could indicate that continued treatment with balinatunfib may present an unreasonable risk for the participant.
  • Participants who in the parent study had documented nonadherence to IMP or to standard therapies for CD or UC, or who used a prohibited medication concomitant with IMP or during a temporary IMP discontinuation period.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    CD cohort: balinatunfib dose regimen 1

    Participants will receive balinatunfib dose regimen 1

    Drug: balinatunfib

  • Experimental
    CD cohort: balinatunfib dose regimen 2

    Participants will receive balinatunfib dose regimen 2

    Drug: balinatunfib

  • Experimental
    CD cohort: balinatunfib dose regimen 3

    Participants will receive balinatunfib dose regimen 3

    Drug: balinatunfib

  • Placebo comparator
    CD cohort: Placebo

    Participants will receive balinatunfib-matching placebo

    Drug: balinatunfib-matching placebo

  • Experimental
    UC cohort: balinatunfib dose regimen 1

    Participants will receive balinatunfib dose regimen 1

    Drug: balinatunfib

  • Experimental
    UC cohort: balinatunfib dose regimen 2

    Participants will receive balinatunfib dose regimen 2

    Drug: balinatunfib

  • Experimental
    UC cohort: balinatunfib dose regimen 3

    Participants will receive balinatunfib dose regimen 3

    Drug: balinatunfib

  • Placebo comparator
    UC cohort: Placebo

    Participants will receive balinatunfib-matching placebo

    Drug: balinatunfib-matching placebo

Interventions

  • Pharmaceutical form:Tablet -Route of administration:Oral

    Also known as: SAR441566

  • Drugbalinatunfib-matching placebo

    Pharmaceutical form:Tablet -Route of administration:Oral

06

What researchers measure

Primary outcomes

  1. Number of participants with Crohn's Disease with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)

    Time frame: Up to End of Study (approximately 106 weeks)

  2. Number of participants with ulcerative colitis with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)

    Time frame: Up to End of Study (approximately 106 weeks)

Secondary outcomes

  1. Proportion of participants with Crohn's Disease in endoscopic remission based on simple endoscopic score for Crohn's disease (SES-CD)

    Endoscopic remission is defined as SES-CD ≤4 points (SES CD ≤2 points for isolated ileal disease) and a SES-CD decrease ≥2 points with no SES-CD subscore \>1 point from baseline. The SES-CD evaluates 4 endoscopic items (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.

    Time frame: Week 52

  2. Proportion of participants with Crohn's Disease in endoscopic remission based on simple endoscopic score for Crohn's disease (SES-CD)

    Endoscopic remission is defined as SES-CD ≤4 points (SES CD ≤2 points for isolated ileal disease) and a SES-CD decrease ≥2 points with no SES-CD subscore \>1 point from baseline. The SES-CD evaluates 4 endoscopic items (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.

    Time frame: Week 104

  3. Proportion of participants with Crohn's Disease in clinical remission based on Crohn's disease activity index (CDAI)

    Clinical remission is defined as CDAI \<150. The CDAI score is composed of eight items: 3 of them (abdominal pain, stool frequency and general well-being) completed by the participant and the others (use of anti-diarrheal medications, extraintestinal complications, palpable abdominal mass, hematocrit levels, and body weight) assessed and reported by the clinician. The CDAI is derived from summing up the weighted individual scores of eight items. Scores on the CDAI scale range from 0 to 600, with higher scores indicating more severe disease.

    Time frame: Week 52

  4. Proportion of participants with Crohn's Disease in clinical remission based on Crohn's disease activity index (CDAI)

    Clinical remission is defined as CDAI \<150. The CDAI score is composed of eight items: 3 of them (abdominal pain, stool frequency and general well-being) completed by the participant and the others (use of anti-diarrheal medications, extraintestinal complications, palpable abdominal mass, hematocrit levels, and body weight) assessed and reported by the clinician. The CDAI is derived from summing up the weighted individual scores of eight items. Scores on the CDAI scale range from 0 to 600, with higher scores indicating more severe disease.

    Time frame: Week 104

  5. Proportion of participants with ulcerative colitis in clinical remission based on modified Mayo Score (mMS)

    Clinical remission by modified Mayo score (mMS) is defined as a mMS score of 0 to 2, including stool frequency (SF) of 0 or 1, rectal bleeding (RB) subscore of 0, and centrally read modified Mayo Endoscopic Subscore \[mMES\] of 0 or 1 (score of 1 modified to exclude friability).Each component of the mMS (SF, RB, and mMES) is scored from 0 to 3. The total mMS ranges from 0 to 9 with higher scores indicating greater disease severity

    Time frame: Week 52

  6. Proportion of participants with ulcerative colitis in clinical remission based on modified Mayo Score (mMS)

    Clinical remission by modified Mayo score (mMS) is defined as a mMS score of 0 to 2, including stool frequency (SF) of 0 or 1, rectal bleeding (RB) subscore of 0, and centrally read modified Mayo Endoscopic Subscore \[mMES\] of 0 or 1 (score of 1 modified to exclude friability).Each component of the mMS (SF, RB, and mMES) is scored from 0 to 3. The total mMS ranges from 0 to 9 with higher scores indicating greater disease severity

    Time frame: Week 104

07

Study locations

10 sites
  • Texas Digestive Disease Consultants - Southlake- Site Number : 8400005
    Southlake, Texas 76092, United States
  • Investigational Site Number : 0320001
    Buenos Aires, 1061, Argentina
  • Investigational Site Number : 1000001
    Gorna Oryahovitsa, 5100, Bulgaria
  • Investigational Site Number : 1520016
    Santiago, Reg Metropolitana de Santiago 7500010, Chile
  • Investigational Site Number : 1520010
    Santiago, Reg Metropolitana de Santiago 8331143, Chile
  • Investigational Site Number : 1520012
    Santiago, Reg Metropolitana de Santiago 8380456, Chile
  • Investigational Site Number : 1560002
    Guangzhou, 510080, China
  • Investigational Site Number : 1560032
    Shanghai, 200120, China
  • Investigational Site Number : 2030001
    Olomouc, 779 00, Czechia
  • Investigational Site Number : 3800002
    Milan, Milano 20132, Italy
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2026 to primary completion in Sep 2026, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2025
First posted
Oct 29, 2025
StartActual
May 19, 2026
Primary completionActual
Sep 29, 2026
CompletionActual
Oct 15, 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Business decision
changed Oct 22, 2026
Primary completion
Sep 30, 2026→Sep 29, 2026 (actual)
Oct 22, 2026
Study completion
Oct 14, 2026→Oct 15, 2026 (actual)
Oct 22, 2026
Enrollment
325 (estimated)→7 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Active, not recruiting→Terminated
    Why stopped Business decision
    Primary completion Sep 30, 2026→Sep 29, 2026 (now actual)
    Study completion Oct 14, 2026→Oct 15, 2026 (now actual)
    Enrollment 325 (estimated)→7 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07222189
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 29, 2025
Start date
May 19, 2026
Primary completion
Sep 29, 2026
Completion
Oct 15, 2026
Last update
Oct 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Balinatunfib

Start the discussion